Adding Ruxolitinib to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Original title: Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study, so we still do not know if the drug helps.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether adding a drug called ruxolitinib to usual treatment helps people with newly diagnosed glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
Who this trial is for. This study is for people who were recently diagnosed with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. It tests a study drug called ruxolitinib added to the usual treatment, which is radiation and temozolomide. Half the people get the study drug plus the usual treatment. Half get the usual treatment only. Who goes in which group is picked at random, like a coin flip.
Where it stands. This study has not reported results. It is looking at how safe ruxolitinib is with the usual treatment, and whether adding it works better. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Right now this tells us nothing about whether ruxolitinib helps. It is being tested to find that out. If you were recently diagnosed with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, you could ask your care team whether a study like this is worth looking into for you. They can explain the usual treatment and what taking part would involve.
What it doesn't mean: This does not mean ruxolitinib is a proven treatment for glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. A trial is a test. Nobody knows yet if the study drug helps, and it may not. Being in a study is not a guarantee that you will do better. Some people in this study get the usual treatment without the study drug. This is not a cure, and it is not a promise of one. Whether anyone can join is decided by the trial team.
Source: ClinicalTrials.gov, July 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.